Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDREW J SULICH

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1508946385
CMS profile
203983
Location
SAINT CLAIR SHORES, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$231,452.55

532 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 10 of 11; records 451–500 of 532 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDREW J SULICH

NPI 1508946385 · CMS profile ID 203983

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SAINT CLAIR SHORES, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 10 of 11; records 451–500 of 532 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508946385?year=2023&recipient=provider&page=10#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDREW J SULICH, NPI 1508946385, CMS profile ID 203983. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 10 of 11; records 451–500 of 532 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508946385?year=2023&recipient=provider&page=10#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ANDREW J SULICH, NPI 1508946385, CMS profile ID 203983. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 10 of 11; records 451–500 of 532 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508946385?year=2023&recipient=provider&page=10#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ANDREW J SULICH, NPI 1508946385, CMS profile ID 203983, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 10 of 11; records 451–500 of 532 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1508946385?year=2023&recipient=provider&page=10#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

532 matching records · $231,452.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 532 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 451–500 of 532.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $1,200.0002/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999162555 CMS
Janssen Biotech, Inc. $28.4702/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988291377 CMS
Lilly USA, LLC $19.4002/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031256995 CMS
PFIZER INC. $1.7802/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050586843 CMS
PFIZER INC. $13.8602/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050659783 CMS
UCB, Inc. $9.8802/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021459659 CMS
UCB, Inc. $0.6102/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021470617 CMS
UCB, Inc. $925.0002/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021484729 CMS
Amgen Inc. $28.4302/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019801955 CMS
Janssen Biotech, Inc. $14.3602/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988291327 CMS
Amgen Inc. $15.5002/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019801925 CMS
Lilly USA, LLC $2,012.5002/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031255439 CMS
PFIZER INC. $1.9202/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049549211 CMS
PFIZER INC. $4.2402/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050537971 CMS
Amgen Inc. $22.4902/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019802021 CMS
Aurinia Pharma U.S., Inc. $25.2502/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057753063 CMS
UCB, Inc. $925.0002/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021484725 CMS
AstraZeneca Pharmaceuticals LP $930.0002/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014414885 CMS
AstraZeneca Pharmaceuticals LP $50.0002/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011799911 CMS
AstraZeneca Pharmaceuticals LP $30.0002/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015648039 CMS
AstraZeneca Pharmaceuticals LP $15.0002/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015665565 CMS
AstraZeneca Pharmaceuticals LP $15.0002/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016182011 CMS
AstraZeneca Pharmaceuticals LP $25.0002/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011406497 CMS
AstraZeneca Pharmaceuticals LP $238.4502/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014394287 CMS
AstraZeneca Pharmaceuticals LP $134.6602/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015919937 CMS
AstraZeneca Pharmaceuticals LP $520.4802/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016053653 CMS
Novartis Pharmaceuticals Corporation $22.6602/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993256661 CMS
AstraZeneca Pharmaceuticals LP $14.5502/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015342421 CMS
E.R. Squibb & Sons, L.L.C. $2.0302/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015488429 CMS
UCB, Inc. $20.9502/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021459689 CMS
AbbVie Inc. $13.8602/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999162551 CMS
Amgen Inc. $20.2702/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020534017 CMS
AstraZeneca Pharmaceuticals LP $3,250.0002/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014609471 CMS
Horizon Therapeutics plc $14.5902/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987080649 CMS
Amgen Inc. $21.5602/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019801951 CMS
Amgen Inc. $8.7702/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019802055 CMS
AstraZeneca Pharmaceuticals LP $3,700.0002/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015668889 CMS
E.R. Squibb & Sons, L.L.C. $16.4902/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015488425 CMS
Novartis Pharmaceuticals Corporation $79.5002/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993256639 CMS
UCB, Inc. $26.1902/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021459717 CMS
UCB, Inc. $3.3702/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021470645 CMS
GlaxoSmithKline, LLC. $650.0002/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001818215 CMS
Novartis Pharmaceuticals Corporation $37.5202/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993256641 CMS
PFIZER INC. $17.8302/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050642357 CMS
AstraZeneca Pharmaceuticals LP $1,154.7401/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011411475 CMS
Novartis Pharmaceuticals Corporation $16.7801/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993256659 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $5,750.0001/27/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993422857 CMS
SANOFI-AVENTIS U.S. LLC $14.5801/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049790405 CMS
Janssen Biotech, Inc. $13.2301/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988291337 CMS
UCB, Inc. $29.6901/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021459729 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $407,012.04 706
PY2020 $141,289.79 330
PY2021 $227,294.44 447
PY2022 $199,128.78 536
PY2023 $231,452.55 532
PY2024 $255,723.19 580
PY2025 $285,559.19 587

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $369,270.39 23
PY2024 Principal investigator $290,101.32 14
PY2023 Principal investigator $155,418.57 10
PY2022 Recipient $51.00 1
PY2022 Principal investigator $144,163.05 5
PY2021 Recipient $434.17 2
PY2021 Principal investigator $284,035.67 27
PY2020 Recipient $302.85 1
PY2020 Principal investigator $233,071.76 52
PY2019 Recipient $84.20 1
PY2019 Principal investigator $144,228.05 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,630.30 12/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202529694
Principal investigator 1 ABBVIE INC. $680.00 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202526612
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $850.00 12/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289188
Principal investigator 1 Novartis Pharmaceuticals Corporation $391.45 12/01/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190302239
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $800.00 12/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289111
Principal investigator 1 ABBVIE INC. $4,080.00 11/20/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202525022
Principal investigator 1 Novartis Pharmaceuticals Corporation $17.12 11/15/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190302231
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288237
Principal investigator 1 Novartis Pharmaceuticals Corporation $144.26 06/27/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190302237
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,500.00 05/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280404
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 05/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223279908
Principal investigator 1 ABBVIE INC. $13,000.00 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202483915
Principal investigator 1 UCB SA $656.83 03/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN, LLC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658428
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,000.00 03/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223276335
Principal investigator 1 UCB SA $84,619.00 03/06/2025 Non-covered Recipient Entity
Clinical Research Institute Of Michigan, Llc
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659108
Principal investigator 1 Novartis Pharmaceuticals Corporation $222,337.87 03/03/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190302235
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,305.00 02/20/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190300599
Principal investigator 1 Novartis Pharmaceuticals Corporation $750.00 02/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190300597
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,500.00 02/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190300601
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,000.00 02/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN LLC
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190300607
Principal investigator 1 UCB SA $181.54 01/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE OF MICHIGAN, LLC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658306
Principal investigator 1 Novartis Pharmaceuticals Corporation $85.60 01/15/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190302233
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,941.42 01/01/2025 Non-covered Recipient Entity
SHORES RHEUMATOLOGY
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190302241